Paper
Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.
Published Dec 1, 2016 · Mei Han, Shan Li, Jing Ai
Bioorganic & medicinal chemistry letters
Q2 SJR score
11
Citations
1
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides show promising potential as novel RET kinase inhibitors for cancer therapy.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
Vandetanib shows dramatic response in metastatic non-small-cell lung cancer patients with RET fusions, suggesting its potential as a targeted therapy for this subpopulation.
2016·69citations·G. Falchook et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Pz-1, a novel RET inhibitor, effectively targets multiple oncogenic pathways and shows no detectable toxicity at high concentrations, offering a large therapeutic window.
2015·39citations·Brendan Frett et al.·Angewandte Chemie
Angewandte Chemie
RET revisited: expanding the oncogenic portfolio
Targeting RET in cancer therapy may have potential long-term pitfalls due to its complex roles in neural lineage survival and tumor-associated inflammation.
2014·447citations·L. Mulligan·Nature Reviews Cancer
Nature Reviews Cancer
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Lenvatinib shows antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.
2013·248citations·K. Okamoto et al.·Cancer letters
Cancer letters
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Ponatinib is a potent inhibitor of RET kinase, particularly effective against vandetanib-resistant V804M/L mutations, suggesting its potential as a treatment for RET+ tumors.
2013·78citations·L. Mologni et al.·Molecular and Cellular Endocrinology
Molecular and Cellular Endocrinology
Citations
Current Advancement in the Oxadiazole-Based Scaffolds as Anticancer Agents
Oxadiazole-based scaffolds show promising anticancer activity by inhibiting various enzymes and growth factors, offering a promising future in drug development as antineoplastic agents.
2021·7citations·Garima Kapoor et al.·Polycyclic Aromatic Compounds
Polycyclic Aromatic Compounds
Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.
Small molecule RET protein kinase inhibitors have developed in the past decade, targeting various hinge binder chemotypes, offering potential for targeted cancer therapy.
2020·11citations·Cong-Cong Jia et al.·Future medicinal chemistry
Future medicinal chemistry
Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds
Oxadiazole scaffolds show promising anticancer activity when modified to selectively interact with biological targets, such as enzymes, globular proteins, and nucleic acids, offering potential for novel drug development.
2020·35citations·A. Benassi et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery
Recent advances in 1,2,4-oxadiazole-based compounds have led to the discovery of several accessible drugs with unique bioisosteric properties and wide biological activities.
2020·104citations·Karol Biernacki et al.·Pharmaceuticals
Pharmaceuticals
Screening of medicinal plants traditionally used in Peruvian Amazon for in vitro antioxidant and anticancer potential
Dysphania ambrosioides, a traditional Peruvian medicinal plant, shows promising antioxidant and anti-proliferative effects on various cancer cells, warranting further research for potential practical use.
2019·20citations·Jan Tauchen et al.·Natural Product Research
Natural Product Research
Novel targeted therapeutics for MEN2.
New, more potent, and selective RET inhibitors or combinatorial strategies may lead to more effective treatments for MEN2 and sporadic MTC in the future.
2018·15citations·S. Redaelli et al.·Endocrine-related cancer
Endocrine-related cancer
Recent advance in oxazole-based medicinal chemistry.
Oxazole compounds show wide potential as medicinal agents for treating various diseases, with recent research highlighting their antibacterial, antifungal, antiviral, antitubercular, anticancer, and anti-inflammatory properties.
2018·243citations·Hui-Zhen Zhang et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Synthesis and in vitro antiproliferative activities of (5-aryl-1,2,4-oxadiazole-3-yl) methyl d-ribofuranosides.
D-ribofuranoside derivatives with 1,2,4-oxadiazolic rings show significant antiproliferative activity against cancer cell lines, with the most potent showing better selectivity towards resistant colon cancer cell line WiDr.
2017·8citations·Romina E Avanzo et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
RET tyrosine kinase inhibitors show promising preclinical activity in treating various human malignancies, including thyroid cancer.
2017·29citations·V. De Falco et al.·Best practice & research. Clinical endocrinology & metabolism
Best practice & research. Clinical endocrinology & metabolism